Esperion Therapeutics ESPR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$25.2M— | —— | -$31.33M-146% | -$12.73M+68.5% | -$40.46M-89.8% | ||
| $27K+3.8% | $26K0.0% | $26K-3.7% | $27K+3.8% | $26K-3.7% | ||
| $2.5M+4.8% | $2.39M+1.6% | $2.35M-12.0% | $2.67M+8.3% | $2.47M-12.1% | ||
| -$27.72M— | —— | -$4.29M+86.4% | -$31.42M-38.9% | -$22.63M+35.3% | ||
| $189K— | $0— | $0— | $0— | $0— | ||
| -$189K— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $16.22M-46.2% | $30.16M+183% | $10.67M+274% | $2.85M+138% | -$7.5M-121% | ||
| -$11.69M-116% | $75.41M+1,081% | $6.39M+122% | -$28.57M+5.2% | -$30.13M-68,573% | ||
| -$27.91M— | —— | -$4.29M+86.4% | -$31.42M-38.9% | -$22.63M+35.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Esperion Therapeutics generate?
- Esperion Therapeutics (ESPR) generated -$86.1M in operating cash flow over the trailing twelve months.
- What is Esperion Therapeutics's free cash flow?
- After $189.0K of capital expenditures, Esperion Therapeutics's free cash flow was -$86.2M over the trailing twelve months, down 129.5% year over year.
- Where does Esperion Therapeutics's cash flow data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
